Skip to Content
Søk Menu

ASCO 2019: Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relateret indhold

ASCO GU 2024: Updated Results from AVENANCE – Real-World Effectiveness of Avelumab in Patients with Advanced Urothelial Carcinoma

/ Sofie Pohl
ASCOGU24Gynekologisk kreft

The 2024 ASCO Genitourinary Cancers Symposium Will Be Covered by BestPractice Nordic

/ Sofie Pohl
ASCOGU24Gynekologisk kreft
Kristina Lindemann

ESMO 2023 Highlights: Practice-Changing Research in Gynecologic Cancers

/ Kristina Lindemann
ESMO23Gynekologisk kreftPasientinvolvering Play the Video 05:30
Kristina Lindemann

Potential New Standard of Care for Locally Advanced Cervical Cancer

/ Kristina Lindemann
ESMO23Gynekologisk kreft Play the Video 03:28
Mansoor Raza Mirza

Optimizing PARP Inhibitor Therapy for Ovarian Cancer

/ Mansoor Raza Mirza
ESMO23Gynekologisk kreft Play the Video 02:45
Kristina Lindemann

Oppdatering fra ESMO 2023 med fokus på kreft i livmorhals-, livmor- og endometrie

/ Kristina Lindemann
ESMO23Gynekologisk kreft Play the Video 04:30

Selected ESMO 2023 Highlights: Endometrial Cancer Treatment

/ Shannon Westin
ESMO23Gynekologisk kreft Play the Video 1:38
Mansoor Raza Mirza

New Treatment Possibilities for Patients with Recurrent or Primary Advanced Endometrial Cancer

/ Mansoor Raza Mirza
ESMO23Gynekologisk kreft Play the Video 4:31
Shannon Westin

Insights on Duo-E Trial: Advancing Endometrial Cancer Treatment with Olaparib

/ Shannon Westin
ESMO23Gynekologisk kreft Play the Video 4:06
Back to top